top of page
Dabrafenib
Anti-neoplastic
MECHANISM OF ACTION
TKI; Inhibits BRAF, inhibiting tumor growth.
MECHANISM OF KIDNEY INJURY
AIN reported and glomerular sclerosis
CLINICAL KIDNEY SYNDROME
Unclear but causes cardiomyopathy , QT prolongation, skin rashes, and VTE
CARDIOVASCULAR ADVERSE EFFECTS
n/a
LYTE ABNORMALITIES
RISK FACTORS
MITIGATION STRATEGIES
SUGGESTIONS
NOTES/COMMENTS
eGFR < 60 ml/min, no dose adjustment
PHARMACOKINETICS
Molecular Weight
519
Volume of Distribution
70.3 L
Plasma Protein Binding
99%
Metabolism
Bioavailability
Half-life elimination
8 hours
Time to peak
Excretion
Feces 71% Urine 23%
Dialyzable?
REF:
PMID: 35029901
PATHOLOGY SLIDES:
ENTRY UPDATES:
Raad Chowdhury
United States
Sep 25, 2022
bottom of page